Key transactions
Edgemond James, who serves as Chief Financial Officer and Treasurer of United Therapeutics Corp (NASDAQ: UTHR), sold 7,762 shares of the company’s common stock on April 2, 2026. The proceeds from those sales were approximately $5.6 million. The trades were completed in a series of executions at prices spanning $551.8638 to $571.6533.
On the same day, James exercised stock options covering 10,000 shares at an exercise price of $135.42, incurring a total cost of $1,354,199. After these transactions, his direct ownership in United Therapeutics stands at 18,876 shares. The filings indicate the transactions were carried out under a Rule 10b5-1 trading plan.
Share performance and valuation signals
United Therapeutics shares have climbed 93% over the past 12 months and are currently quoted at $559.65, with a market capitalization reported at $24.45 billion. Separately, InvestingPro’s analysis referenced in filings notes that the stock presently appears overvalued relative to its Fair Value. The InvestingPro platform is cited as offering 13 additional ProTips for UTHR, alongside financial health metrics and detailed Pro Research Reports for deeper review.
Analyst reactions tied to clinical progress
Market participants and analysts have taken a more favorable stance following positive Phase 3 TETON-1 trial data for Tyvaso in the treatment of idiopathic pulmonary fibrosis (IPF). Jefferies raised its price target on United Therapeutics to $733 from $668 and maintained a Buy rating, citing results that exceeded both investor and firm expectations and that the data increased the probability of success for the IPF indication. H.C. Wainwright also lifted its target to $660 from $600 and kept a Buy rating, pointing to the TETON-1 results as a major contributor. Bank of America Securities increased its price target to $626 from $569 while maintaining a Neutral rating, characterizing the trial as a second confirmatory study.
Those analyst moves reflect a positive market reception to the TETON-1 outcomes, and the share-price response over the past year is consistent with heightened investor interest around the program.
Related sector activity
The ripple effects of the TETON-1 readout extended to peers. Insmed received an upgrade from Morgan Stanley to Overweight and a higher price target of $212, a shift Morgan Stanley attributed in part to strong prescribing trends for Insmed’s Brinsupri in the U.S. market, based on the firm’s survey data.
What the filings show and what remains explicit
Regulatory filings document the size, timing and mechanics of James’ disposition and option exercise and note the use of a 10b5-1 trading plan. The public information cited in filings also includes third-party analysis and a series of analyst price-target revisions tied explicitly to the TETON-1 trial results. Beyond these items, the filings referenced do not provide additional commentary on motives, future insider activity or management intent.